BBI-355 is under clinical development by Boundless Bio and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Squamous Non-Small Cell Lung Cancer have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BBI-355’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BBI-355 overview
BBI-335 is under development for the treatment of non-small cell lung cancer, non-small cell lung adenocarcinoma, non-small cell squamous lung cancer, head and neck squamous cell carcinoma, esophageal cancer, gastric cancer, breast cancer, bladder cancer, ovarian cancer, endometrial cancer, liposarcoma. The drug candidate acts by targeting Checkpoint Kinase 1 (CHK1). It is administered through oral route.
Boundless Bio overview
Boundless Bio is a biopharmaceutical company that discovers and develops drugs for extrachromosomal DNA (ecDNA) based intractable cancer. Its pipeline includes BBI-355, BBI-825, ecDTx 3 and echo. Its pipeline candidates treat extrachromosomal DNA (ecDNA) replication stress, ecDNA assembly and repair, ecDNA segregation, new ecDNA targets and mechanisms, and ecDNA diagnostic It utilizes the spyglass platform, a suite of proprietary ecDNA-driven and pair-matched tumor models with imaging and molecular analytical tools to identify novel oncotargets. The company’s platform technology enables the development of therapies for ecDNA-driven tumors. Boundless Bio is headquartered in San Diego, California, the US.
For a complete picture of BBI-355’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
